Soluble CD40 ligand (sCD40L) provides a new delivery system for targeted treatment: SCD40L-caspase 3 chimeric protein for treating B-cell malignancies

Cancer

Volumn 118, Issue 24, 2012, Pages 6089-6104

  Kedar, Rotem ^a   Sabag, Ofra ^a   Licthenstein, Michal ^a   Lorberboum Galski, Haya ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

apoptosis; B cell malignancies; caspase 3; chimeric proteins; soluble CD40 ligand; targeted therapy

Indexed keywords

CASPASE 3; CD40 LIGAND; HYBRID PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN 38; RNA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CYCLE REGULATION; CELL LEVEL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DRUG DELIVERY SYSTEM; DRUG PURIFICATION; ENZYME ACTIVITY; GENE CONSTRUCT; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INTERNALIZATION; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT;

ANTIGENS, CD40; APOPTOSIS; B-LYMPHOCYTES; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CASPASE 3; CD40 LIGAND; CELL CYCLE; EXOTOXINS; HUMANS; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL; PROTO-ONCOGENE PROTEINS C-BCL-2; PSEUDOMONAS AERUGINOSA; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84870700351     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27654     Document Type: Article

References (39)

1. Tobinai K,. Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma. Int J Clin Oncol. 2003; 8: 212-223.
2. Ravandi F, O'Brien S,. Alemtuzumab in CLL and other lymphoid neoplasms. Cancer Invest. 2006; 24: 718-725.
3. Villamor N, Montserrat E, Colomer D,. Mechanism of action and resistance to monoclonal antibody therapy. Semin Oncol. 2003; 30: 424-433.
4. Reeder CB, Ansell SM,. Novel therapeutic agents for B-cell lymphoma: developing rational combinations. Blood. 2011; 117: 1453-1462.
5. Aqeilan R, Kedar R, Ben-Yehudah A, Lorberboum-Galski H,. Mechanism of action of interleukin-2 (IL-2)-Bax, an apoptosis-inducing chimaeric protein targeted against cells expressing the IL-2 receptor. Biochem J. 2003; 370 (pt 1): 129-140.
6. Aqeilan R, Yarkoni S, Lorberboum-Galski H,. Interleukin-2-Bax: a novel prototype of human chimeric proteins for targeted therapy. FEBS Lett. 1999; 457: 271-276.
7. Azar Y, Lorberboum-Galski H,. GnRH-Bik/Bax/Bak chimeric proteins target and kill adenocarcinoma cells; the general use of pro-apoptotic proteins of the Bcl-2 family as novel killing components of targeting chimeric proteins. Apoptosis. 2000; 5: 531-542.
8. Segel MJ, Aqeilan R, Zilka K, et al. Effect of IL-2-Bax, a novel interleukin-2-receptor-targeted chimeric protein, on bleomycin lung injury. Int J Exp Pathol. 2005; 86: 279-288.
9. Ben-Yehudah A, Aqeilan R, Robashkevich D, Lorberboum-Galski H,. Using apoptosis for targeted cancer therapy by a new gonadotropin releasing hormone-DNA fragmentation factor 40 chimeric protein. Clin Cancer Res. 2003; 9: 1179-1190.
10. Lichtenstein M, Ben-Yehudah A, Belostotsky R, et al. Utilizing a GnRH-based chimeric protein for the detection of adenocarcinoma. Int J Oncol. 2005; 27: 143-148.
11. Shteingart S, Rapoport M, Grodzovski I, et al. Therapeutic potency of IL-2-caspase 3 targeted treatment in a murine experimental model of inflammatory bowel disease. Gut. 2009; 58: 790-798.
12. Irony-Tur-Sinai M, Lichtenstein M, Brenner T, Lorberboum-Galski H,. IL-2-caspase3 chimeric protein controls lymphocyte reactivity by targeted apoptosis, leading to amelioration of experimental autoimmune encephalomyelitis. Int Immunopharmacol. 2009; 9: 1236-1243.
13. van Kooten C, Banchereau J,. CD40-CD40 ligand. J Leukoc Biol. 2000; 67: 2-17.
14. Mazzei GJ, Edgerton MD, Losberger C, et al. Recombinant soluble trimeric CD40 ligand is biologically active. J Biol Chem. 1995; 270: 7025-7028.
15. Francisco JA, Siegall CB,. Single-chain immunotoxins targeted to CD40 for the treatment of human B-lineage hematologic malignancies. Leuk Lymphoma. 1998; 30: 237-245.
16. Schonbeck U, Mach F, Libby P,. CD154 (CD40 ligand). Int J Biochem Cell Biol. 2000; 32: 687-693.
17. Buchner J, Pastan I, Brinkmann U,. A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal Biochem. 1992; 205: 263-270.
18. Manning E, Pullen SS, Souza DJ, Kehry M, Noelle RJ,. Cellular responses to murine CD40 in a mouse B cell line may be TRAF dependent or independent. Eur J Immunol. 2002; 32: 39-49.
19. Hostager BS, Catlett IM, Bishop GA,. Recruitment of CD40 and tumor necrosis factor receptor-associated factors 2 and 3 to membrane microdomains during CD40 signaling. J Biol Chem. 2000; 275: 15392-15398.
20. Chen J, Chen L, Wang G, Tang H,. Cholesterol-dependent and -independent CD40 internalization and signaling activation in cardiovascular endothelial cells. Arterioscler Thromb Vasc Biol. 2007; 27: 2005-2013.
21. Schagger H, von Jagow G,. Blue native electrophoresis for isolation of membrane protein complexes in enzymatically active form. Anal Biochem. 1991; 199: 223-231.
22. Ong YL, McMullin MF, Bailie KE, Lappin TR, Jones FG, Irvine AE,. High bax expression is a good prognostic indicator in acute myeloid leukaemia. Br J Haematol. 2000; 111: 182-189.
23. Kreitman RJ,. Immunotoxins for targeted cancer therapy [serial online]. AAPS J. 2006; 8: E532-E551.
24. Kreitman RJ,. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs. 2009; 23: 1-13.
25. Pulczynski S,. Antibody-induced modulation and intracellular transport of CD10 and CD19 antigens in human malignant B cells. Leuk Lymphoma. 1994; 15: 243-252.
26. Mansfield E, Chiron MF, Amlot P, Pastan I, FitzGerald DJ,. Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells. Biochem Soc Trans. 1997; 25: 709-714.
27. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol. 2005; 23: 6719-6729.
28. Kreitman RJ, Stetler-Stevenson M, Margulies I, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009; 27: 2983-2990.
29. Ben-Yehudah A, Yarkoni S, Nechushtan A, Belostotsky R, Lorberboum-Galski H,. Linker-based GnRH-PE chimeric proteins inhibit cancer growth in nude mice. Med Oncol. 1999; 16: 38-45.
30. Rabbani A, Finn RM, Ausio J,. The anthracycline antibiotics: antitumor drugs that alter chromatin structure. Bioessays. 2005; 27: 50-56.
31. Wang LG, Liu XM, Kreis W, Budman DR,. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol. 1999; 44: 355-361.
32. Imai A, Suzuki T, Sugitani A, et al. A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys. Transplantation. 2007; 84: 1020-1028.
33. Gilson CR, Milas Z, Gangappa S, et al. Anti-CD40 monoclonal antibody synergizes with CTLA4-Ig in promoting long-term graft survival in murine models of transplantation. J Immunol. 2009; 183: 1625-1635.
34. Li XL, Menoret S, Le Mauff B, Angin M, Anegon I,. Promises and obstacles for the blockade of CD40-CD40L interactions in allotransplantation. Transplantation. 2008; 86: 10-15.
35. Kirk AD, Blair PJ, Tadaki DK, Xu H, Harlan DM,. The role of CD154 in organ transplant rejection and acceptance. Philos Trans R Soc Lond B Biol Sci. 2001; 356: 691-702.
36. Santilli F, Basili S, Ferroni P, Davi G,. CD40/CD40L system and vascular disease. Intern Emerg Med. 2007; 2: 256-268.
37. Advani R, Forero-Torres A, Furman RR, et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol. 2009; 27: 4371-4377.
38. Furman RR, Forero-Torres A, Shustov A, Drachman JG,. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2010; 51: 228-235.
39. Hussein M, Berenson JR, Niesvizky R, et al. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica. 2010; 95: 845-848.